| Market Cap | ₹4,697.08 CrPharmaceuticals |
|---|---|
| Revenue TTM | ₹707.52 CrAnnual Operating |
| Day RSI | 86.64Overbought Zone |
| Net Profit TTM | ₹115.17 CrTrailing 12 Months |
Key highlights
- RPG Life Sciences will exclusively market and distribute Naprosyn ES across its pan-India network
- The product is a first-time combination of Naproxen and Esomeprazole launched in India
- Archerchem Healthcare serves as the exclusive supplier and co-developer of the formulation
- The formulation addresses unmet needs for patients at risk of gastrointestinal complications
- The launch leverages the established brand equity and doctor trust of the Naprosyn brand
The Product — What It Is
Naprosyn ES is a fixed-dose combination of Naproxen, a nonsteroidal anti-inflammatory drug, and Esomeprazole, a proton pump inhibitor. It is specifically formulated to address the therapeutic requirements of patients needing long-term pain management who are simultaneously at risk of developing gastrointestinal complications like ulcers. By integrating gastro-protection directly into the anti-inflammatory delivery, the product aims to enhance patient compliance.
This launch marks the first time this specific combination has been introduced to the Indian pharmaceutical market, catering specifically to elderly and gastro-sensitive populations requiring chronic therapy for inflammatory conditions.
Commercial Opportunity
- RPG Life Sciences holds exclusive rights for the marketing and distribution of Naprosyn ES across India
- The product targets high-volume chronic pain management segments involving super-specialist prescriptions
- Archerchem Healthcare acts as the exclusive supplier and development partner for the differentiated formulation
- The launch aligns with the company focus on building a differentiated portfolio in chronic therapy segments
- Distribution will be driven by RPG Life Sciences' established pan-India network and legacy brand recall
Strategic Fit
The introduction of Naprosyn ES aligns with RPG Life Sciences' broader strategy to build a differentiated portfolio within the chronic therapy segment. By focusing on complex, value-added formulations rather than standard generics, the company aims to strengthen its presence in specialized medical fields. This partnership with Archerchem Healthcare reinforces an R&D-driven approach to patient-centric innovation.
It allows the firm to utilize its robust distribution infrastructure to penetrate the Indian market with a first-to-market combination, potentially securing a competitive advantage in the NSAID category while addressing clinical needs in long-term therapy.
Industry Context
The Indian pharmaceutical sector is witnessing a shift towards complex fixed-dose combinations that improve patient compliance in chronic disease management. With the increasing prevalence of lifestyle-related inflammatory conditions and an aging population, the demand for safer pain management alternatives is rising. Long-term use of traditional drugs often leads to gastric side effects, prompting clinicians to prescribe gastro-protective agents alongside.
Products like Naprosyn ES address this by offering a built-in solution. As the industry moves toward value-added formulations, partnerships between manufacturers and distributors are becoming critical for penetrating diverse healthcare markets.
“At RPG Life Sciences, innovation is rooted in patient centricity. Naprosyn ES is an example of our strong R&D-driven approach to differentiated products, and the long-standing trust that doctors and patients place in the Naprosyn brand.”
“This partnership exemplifies Archerchem’s core strength in developing complex differential formulations. Through our partnership with RPG Life Sciences, we are proud to deliver incremental innovation that enhances medication adherence and brings meaningful benefit to patients across India.”
| Share price | ₹2840 |
|---|---|
| Market capitalisation | ₹4,697.08 Cr |
| Revenue (annual) | ₹707.52 Cr |
| Net profit (annual) | ₹115.17 Cr |
| Revenue (latest quarter) | ₹176.89 Cr-1.74% vs previous quarter |
| Net profit (latest quarter) | ₹29.90 Cr+35.11% vs previous quarter |
| P/E (TTM) | 40.78×Sector 43.07× |
| Promoter holding | 72.95%0.00% QoQ |
| FII holding | 0.87%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by RPG Life Sciences Limited announcing the launch of Naprosyn ES in partnership with Archerchem Healthcare. Market figures from a third-party data provider.
